Dabigatran toxicity is treated by
**Core Concept**
Dabigatran is a direct oral anticoagulant that inhibits **thrombin**, a key enzyme in the coagulation cascade. Its toxicity can lead to severe bleeding. Management of dabigatran toxicity involves reversing its anticoagulant effects.
**Why the Correct Answer is Right**
The correct answer involves the use of **idarucizumab**, a monoclonal antibody fragment that specifically binds to dabigatran, reversing its anticoagulant activity. This mechanism allows for rapid reversal of dabigatran's effects, which is critical in cases of severe bleeding.
**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because it is not a recognized treatment for dabigatran toxicity.
**Option B:** Incorrect as it does not specifically reverse dabigatran's anticoagulant effects.
**Option C:** Incorrect because, while it may be involved in general management, it is not the specific treatment for dabigatran toxicity.
**Clinical Pearl / High-Yield Fact**
Idarucizumab is a specific antidote for dabigatran, making it a crucial agent in managing dabigatran-associated bleeding. Remembering the specific reversal agents for different anticoagulants is key.
**Correct Answer:** D. Idarucizumab.